 | |
| Clinical data | |
|---|---|
| Other names | 17β-[2-[4-[(diethylamino)methyl]-2-methoxyphenoxy]ethyl]-7α-methylestra-1,3,5(10)-trien-3-ol; 17β-[2-[4-[(diethylamino)methyl]-2-methoxyphenoxy]ethyl]-7α-methylestradiol |
| Routes of administration | By mouth[1] |
| ATC code | |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider | |
| UNII |
|
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C33H47NO3 |
| Molar mass | 505.743 g·mol−1 |
| 3D model (JSmol) |
|
| |
| |
TAS-108, also known asSR-16234, is a drug discovered byMasato Tanabe and under development bySRI International andTaiho Pharmaceutical. It is asteroid hormone that has shown signs of treating and preventingbreast cancer, even in patients wheretamoxifen has failed.[2][3]
Masato Tanabe's team at SRI has focused on the development of steroid hormones. A compound discovered in a previous SRI contract from theNational Institutes of Health showed potential – it acted like "anti-estrogen" in the breasts and uterus but like normal estrogen elsewhere in the body, and was more "tissue-selective".[4] A contract was proposed toTaiho Pharmaceutical in July 1996, and within six years and slightly under $3 million (an unusually short amount of time), two new drugs were discovered and tested on people (particularly people for whichtamoxifen has failed): SR-16234 and SR-16287.[4]
The first of those, SR-16234, also inhibited the growth of blood vesselsangiogenesis and accelerated the death of cancer cellsapoptosis and thus was particularly well suited to be an anti-cancer drug.[4] As of August 2010, the drug had been through five Phase I and two Phase II studies,[5] and Phase III studies are being planned.[6]
